Novavax Inc (NVAX)

Price$10.20

Value ScoreB

Growth ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)40.41%

Price vs S&P 500 (4W)21.10%

VGM Score50.92

Market Capitalization$1.66B

P/E Ratio (Annual)3.78x

All Metrics

Book Value / Share (Quarterly)$0.23

P/TBV (Annual)11.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-17.24%

Cash Flow / Share (Quarterly)$-0.59

Price vs S&P 500 (YTD)40.55%

Gross Margin (TTM)84.97%

Net Profit Margin (TTM)-14.73%

EPS (TTM)$-0.61

10-Day Avg Trading Volume5.80M

EPS Excl Extra (TTM)$-0.61

Revenue Growth (5Y)18.76%

EPS (Annual)$2.54

ROI (Annual)-38.19%

Gross Margin (Annual)93.50%

Net Profit Margin (5Y Avg)-45.81%

Cash / Share (Quarterly)$4.81

P/E Basic Excl Extra (TTM)3.80x

Revenue Growth QoQ (YoY)-79.07%

P/E Normalized (Annual)3.78x

ROA (Last FY)-12.02%

Revenue Growth TTM (YoY)-52.48%

EBITD / Share (TTM)$-0.49

ROE (5Y Avg)-43.51%

Operating Margin (TTM)-17.92%

Cash Flow / Share (Annual)$-0.63

P/B Ratio44.25x

P/B Ratio (Quarterly)27.12x

Net Income / Employee (Annual)$587,900

EV / Revenue (TTM)2.90x

Net Interest Coverage (TTM)20.61x

ROA (TTM)-7.42%

EV / EBITDA (TTM)3.83x

EPS Incl Extra (Annual)$2.54

Current Ratio (Annual)0.98x

Quick Ratio (Quarterly)2.38x

3-Month Avg Trading Volume4.78M

52-Week Price Return44.41%

P/E Incl Extra (TTM)3.80x

Revenue / Employee (TTM)$796,200

Tangible BV / Share (Quarterly)$0.78

P/S Ratio (Annual)1.48x

Asset Turnover (Annual)0.44x

52-Week High$11.97

Operating Margin (5Y Avg)-47.20%

EPS Excl Extra (Annual)$2.54

CapEx CAGR (5Y)-36.67%

Tangible BV CAGR (5Y)66.48%

26-Week Price Return54.00%

Quick Ratio (Annual)0.92x

13-Week Price Return0.99%

Total Debt / Equity (Annual)0.75x

Current Ratio (Quarterly)2.48x

Enterprise Value$1.73B

Revenue / Share Growth (5Y)-4.70%

Asset Turnover (TTM)0.50x

Book Value / Share Growth (5Y)-0.67%

Revenue / Employee (Annual)$1,500,000

Inventory Turnover (Annual)8.00x

Pretax Margin (Annual)39.36%

Cash / Share (Annual)$5.77

3-Month Return Std Dev68.77%

Gross Margin (5Y Avg)66.92%

Net Income / Employee (TTM)$-117,300

ROE (Last FY)-66.69%

Net Interest Coverage (Annual)-2.97x

EPS Basic Excl Extra (Annual)$2.54

P/FCF (TTM)15.74x

Receivables Turnover (TTM)17.59x

Total Debt / Equity (Quarterly)6.07x

EPS Incl Extra (TTM)$-0.61

Receivables Turnover (Annual)5.18x

ROI (TTM)40.02%

P/S Ratio (TTM)2.79x

Pretax Margin (5Y Avg)-44.86%

Revenue / Share (Annual)$6.49

Tangible BV / Share (Annual)$8.75

Forward P/E77.23x

Price vs S&P 500 (52W)16.26%

P/E Ratio (TTM)3.80x

Year-to-Date Return51.93%

5-Day Price Return-7.94%

EPS Normalized (Annual)$2.54

ROA (5Y Avg)-33.11%

Net Profit Margin (Annual)39.19%

Month-to-Date Return-6.93%

Cash Flow / Share (TTM)$-5.39

EBITD / Share (Annual)$2.61

Operating Margin (Annual)37.75%

LT Debt / Equity (Annual)0.51x

ROI (5Y Avg)-37.60%

P/E Excl Extra (TTM)3.80x

LT Debt / Equity (Quarterly)4.53x

EPS Basic Excl Extra (TTM)$-0.61

P/TBV (Quarterly)92.41x

P/B Ratio (Annual)11.32x

Inventory Turnover (TTM)8.25x

Pretax Margin (TTM)-14.45%

Book Value / Share (Annual)$8.83

Price vs S&P 500 (13W)-9.67%

Beta2.52x

P/FCF (Annual)6.27x

Revenue / Share (TTM)$3.65

ROE (TTM)283.08%

52-Week Low$6.13

vGradeB

gGradeD

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.06est. -0.23

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.67

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
NVAXNovavax Inc	B	D	C	$10.20
AMGNAmgen Inc	C	C	C	$338.22
GILDGilead Sciences Inc	C	B	C	$128.99
ARGXargenx SE American Depositary Shares	D	A	B	$813.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$155.99
BIIBBiogen Inc. Common Stock	B	D	C	$195.96
BNTXBioNTech SE American Depositary Share	C	C	D	$88.45
MRNAModerna, Inc. Common Stock	C	B	C	$49.06
NBIXNeurocrine Biosciences Inc	C	B	B	$165.11
EXELExelixis Inc	C	B	B	$51.60
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$301.82

About

Novavax Inc is a biotechnology company developing vaccines to prevent a broad range of human infectious diseases, with a focus on both established and emerging disease threats. The company conducts clinical-stage development of novel vaccine candidates, supported by its Swedish subsidiary's manufacturing operations. Its proprietary vaccine technology platform is designed for broad applicability across multiple infectious disease indications, with the majority of revenue generated from the United States.